Alzheon, Inc. | Preserving Future Memories

Alzheon, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease and other neurodegenerative disorders. Their lead product candidate, valiltramiprosate/ALZ-801, is an oral medication currently in Phase 3 trials. Valiltramiprosate targets the formation of neurotoxic amyloid oligomers, believed to be a key driver of Alzheimer's pathogenesis. Alzheon's precision medicine approach focuses on patients with two copies of the APOE4 gene, who have the highest risk of developing Alzheimer's, and they believe valiltramiprosate has the potential to slow, stop, or even prevent the onset of clinical symptoms.

Alzheon's research has led to several key discoveries, including the identification of neurotoxic amyloid oligomers and the development of biomarkers for diagnosis and tracking disease progression. Their commitment to innovation and precision medicine is reflected in their extensive research and development efforts, as well as their collaboration with prominent scientific advisors and institutions. Alzheon's mission is to develop effective and accessible treatments that preserve future memories for Alzheimer's patients and their families.

Alzheon is a clinical-stage biopharmaceutical company committed to developing innovative medicines that directly address the underlying pathology of neurodegenerative disorders. Their mission is to preserve future memories by creating disease-modifying therapies for Alzheimer's and other neurodegenerative diseases, with a particular focus on inhibiting protein misfolding and aggregation. They are currently developing valiltramiprosate/ALZ-801, an oral agent in Phase 3 testing for Alzheimer's disease, which they believe has the potential to significantly slow or stop disease progression, and even prevent the onset of clinical symptoms.

Alzheon, Inc. fosters a passionate and highly experienced team environment, characterized by a deep understanding of neurological and psychiatric disorders. The company values collaboration, innovation, and a commitment to developing products that directly address the underlying pathology of neurodegenerative disorders. Alzheon cultivates an entrepreneurial spirit and encourages its employees to contribute to making the first oral Alzheimer’s disease-modifying therapy a reality for patients and their families.